News

ING Confirms Cash Distribution of €0.161 Per Share to Investors

ING Confirms Cash Distribution of €0.161 Per Share to Investors

ING Announces Cash Payment per Share

ING has officially confirmed a cash payment of €0.161 per share. This decision is part of a considerable effort to distribute up to €2.5 billion to shareholders. The announcement is a reflection of ING's commitment to return value to its investors while supporting its financial stability and growth.

Details of the Cash Distribution

The designated payment will take place on a date yet to be specified. The amount stems from a total cash distribution budget of €500 million, calculated based on 3,096 million ordinary shares as of a recent financial review. This initiative aims to provide shareholders with direct returns while reflecting the company's robust financial health.

Additional Share Buyback Program

In addition to the cash payment, ING is implementing a share buyback program worth up to €2 billion. This program is currently ongoing and is expected to conclude before the end of April in the following financial cycle. The dual strategy of cash distributions alongside share buybacks serves as a testament to ING’s approach to enhancing shareholder value.

Strengthening Financial Ratios

One of the primary objectives of this distribution is to improve the CET1 ratio, positioning it closer to the company’s target of around 12.5%. Maintaining strong financial ratios is crucial for a financial institution like ING, as it speaks volumes about its operational efficiency and stability in volatile markets.

Transparency and Updates

ING is committed to transparency regarding these transactions. Weekly updates on the progress of the buyback program will be provided, ensuring that investors are kept informed about the ongoing initiatives. This aligns with ING's strategy of open communication with its shareholders. Investors can find the latest details under the Investor Relations section of ING's official website.

About ING Group

ING is a leading global financial institution based in Europe, primarily offering a wide range of banking services through ING Bank. With over 60,000 employees, the bank provides retail and wholesale banking options to over 40 countries worldwide. Their commitment to sustainability is reflected in their initiatives aimed at minimizing their carbon footprint and promoting environmentally friendly practices across all operations.

Commitment to ESG Standards

ING is also focused on implementing strong Environmental, Social, and Governance (ESG) principles. Recent ratings from independent research firms indicate that ING's commitment to sustainability continues to strengthen, as showcased by its 'AA' rating from MSCI. This commitment resonates well with investors who prioritize ethical finance and sustainability when making investment decisions.

Shareholder Communication

For any inquiries, shareholders and potential investors can reach out to Christoph Linke through the provided contact details. Communication is a top priority for ING, and they ensure that all concerns from shareholders are addressed timely.

Contact Information for Enquiries

Press: Christoph Linke
Phone: +31 20 576 5000
Email: Christoph.Linke@ing.com

Investor Relations: ING Group Investor Relations
Phone: +31 20 576 6396
Email: Investor.Relations@ing.com

Frequently Asked Questions

What is the announced cash payment per share by ING?

ING has announced a cash payment of €0.161 per share as part of a larger distribution initiative.

What is the total amount ING plans to distribute to shareholders?

ING aims to distribute up to €2.5 billion to its shareholders.

When is the cash payment expected to be executed?

The exact date for the cash payment has not been specified yet.

What is the purpose of the share buyback program?

The share buyback program aims to enhance shareholder value while reinforcing ING's CET1 ratio.

How can investors stay updated on ING's distribution progress?

Investors can find weekly updates on the progress of the buyback and cash distribution in the Investor Relations section of the ING website.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 3

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 12

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
More News Articles